MG
CYTK icon

Michael Gelband’s Cytokinetics CYTK Stock Holding History

Michael Gelband’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$21.2M Buy
249,259
+197,032
+377% +$14.1M 0.14% 120
2026
Q1 		$3.44M Sell
52,227
-290,917
-85% -$18.5M 0.03% 565
2025
Q4 		$21.8M Buy
+343,144
New +$21.3M 0.17% 95
2025
Q2 		– Sell
-85,863
Closed -$3.45M – 1560
2025
Q1 		$3.45M Buy
85,863
+76,539
+821% +$3.52M 0.03% 527
2024
Q4 		$439K Sell
9,324
-108,660
-92% -$5.64M ﹤0.01% 1182
2024
Q3 		$6.23M Buy
117,984
+25,051
+27% +$1.4M 0.04% 345
2024
Q2 		$5.04M Buy
92,933
+47,669
+105% +$2.88M 0.03% 400
2024
Q1 		$3.17M Buy
45,264
+42,130
+1,344% +$3.26M 0.02% 541
2023
Q4 		$262K Sell
3,134
-201,599
-98% -$7.3M ﹤0.01% 1216
2023
Q3 		$6.03M Sell
204,733
-8,159
-4% -$272K 0.06% 330
2023
Q2 		$6.95M Sell
212,892
-57,557
-21% -$2.13M 0.06% 343
2023
Q1 		$9.52M Buy
270,449
+109,116
+68% +$4.45M 0.08% 291
2022
Q4 		$7.39M Buy
+161,333
New +$6.94M 0.11% 247
2022
Q3 		– Sell
-98,740
Closed -$3.88M – 1951
2022
Q2 		$3.88M Buy
+98,740
New +$3.98M 0.05% 493
2022
Q1 		– Sell
-26,013
Closed -$1.19M – 2283
2021
Q4 		$1.19M Sell
26,013
-50,572
-66% -$1.95M 0.01% 982
2021
Q3 		$2.74M Buy
76,585
+45,070
+143% +$1.33M 0.04% 602
2021
Q2 		$624K Sell
31,515
-21,971
-41% -$516K 0.01% 1244
2021
Q1 		$1.24M Buy
+53,486
New +$1.14M 0.02% 797
2020
Q1 		– Sell
-19,384
Closed -$206K – 1179
2019
Q4 		$206K Buy
+19,384
New +$199K ﹤0.01% 1331

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Michael Gelband's CYTK Position: Q2 2026 in Review

Michael Gelband increased its Cytokinetics (CYTK) stake by 377% in Q2 2026, buying an estimated $14.1M and bringing the position to 249,259 shares worth $21.2M. The position accounts for 0.14% of the portfolio, ranked #120.

Michael Gelband first reported a position in CYTK in Q4 2019 and has held it in 19 quarters since. The position peaked at $21.8M in Q4 2025. 479 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • Michael Gelband held 249,259 shares of Cytokinetics worth $21.2M as of Q2 2026.
  • Michael Gelband bought 197,032 Cytokinetics shares in Q2 2026, an estimated $14.1M.
  • Cytokinetics made up 0.14% of Michael Gelband's portfolio in Q2 2026, its #120 holding.
  • Michael Gelband first reported a position in Cytokinetics in Q4 2019 and has held it in 19 quarters since.
  • Michael Gelband's Cytokinetics position peaked at $21.8M in Q4 2025.
  • 479 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on ExodusPoint Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.